Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22848
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTrubiano, Jason A-
dc.contributor.authorVogrin, Sara-
dc.contributor.authorChua, Kyra Y L-
dc.contributor.authorBourke, Jack-
dc.contributor.authorYun, James-
dc.contributor.authorDouglas, Abby-
dc.contributor.authorStone, Cosby A-
dc.contributor.authorYu, Roger-
dc.contributor.authorGroenendijk, Lauren-
dc.contributor.authorHolmes, Natasha E-
dc.contributor.authorPhillips, Elizabeth J-
dc.date2020-03-16-
dc.date.accessioned2020-03-23T22:10:39Z-
dc.date.available2020-03-23T22:10:39Z-
dc.date.issued2020-03-16-
dc.identifier.citationJAMA internal medicine 2020; online first: 16 March-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/22848-
dc.description.abstractPenicillin allergy is a significant public health issue for patients, antimicrobial stewardship programs, and health services. Validated clinical decision rules are urgently needed to identify low-risk penicillin allergies that potentially do not require penicillin skin testing by a specialist. To develop and validate a penicillin allergy clinical decision rule that enables point-of-care risk assessment of patient-reported penicillin allergies. In this diagnostic study, a multicenter prospective antibiotic allergy-tested cohort of 622 patients from 2 tertiary care sites in Melbourne, Australia (Austin Health and Peter MacCallum Cancer Centre) was used for derivation and internal validation of a penicillin allergy decision rule. Backward stepwise logistic regression was used to derive the model, including clinical variables predictive of a positive penicillin allergy test result. Internal validation of the final model used bootstrapped samples and the model scoring derived from the coefficients. External validation was performed in retrospective penicillin allergy-tested cohorts consisting of 945 patients from Sydney and Perth, Australia, and Nashville, Tennessee. Patients who reported a penicillin allergy underwent penicillin allergy testing using skin prick, intradermal, or patch testing and/or oral challenge (direct or after skin testing). Data were collected from June 26, 2008, to June 3, 2019, and analyzed from January 9 to 12, 2019. The primary outcome for the model was any positive result of penicillin allergy testing performed during outpatient or inpatient assessment. From an internal derivation and validation cohort of 622 patients (367 female [59.0%]; median age, 60 [interquartile range{IQR}, 48-71] years) and an external validation cohort of 945 patients (662 female [70.1%]; median age, 55 [IQR, 38-68] years), the 4 features associated with a positive penicillin allergy test result on multivariable analysis were summarized in the mnemonic PEN-FAST: penicillin allergy, five or fewer years ago, anaphylaxis/angioedema, severe cutaneous adverse reaction (SCAR), and treatment required for allergy episode. The major criteria included an allergy event occurring 5 or fewer years ago (2 points) and anaphylaxis/angioedema or SCAR (2 points); the minor criterion (1 point), treatment required for an allergy episode. Internal validation showed minimal mean optimism of 0.003 with internally validated area under the curve of 0.805. A cutoff of less than 3 points for PEN-FAST was chosen to classify a low risk of penicillin allergy, for which only 17 of 460 patients (3.7%) had positive results of allergy testing, with a negative predictive value of 96.3% (95% CI, 94.1%-97.8%). External validation resulted in similar findings. In this study, PEN-FAST was found to be a simple rule that accurately identified low-risk penicillin allergies that do not require formal allergy testing. The results suggest that a PEN-FAST score of less than 3, associated with a high negative predictive value, could be used by clinicians and antimicrobial stewardship programs to identify low-risk penicillin allergies at the point of care.-
dc.language.isoeng-
dc.titleDevelopment and Validation of a Penicillin Allergy Clinical Decision Rule.-
dc.typeJournal Article-
dc.identifier.journaltitleJAMA internal medicine-
dc.identifier.affiliationDepartment of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases, Vanderbilt University Medical Centre, Nashville, Tennesseeen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australiaen
dc.identifier.affiliationDepartment of Allergy and Immunology, Fiona Stanley Hospital, Murdoch, Australiaen
dc.identifier.affiliationFaculty of Medicine and Health, University of Sydney, Sydney, Australiaen
dc.identifier.affiliationCentre for Antibiotic Allergy and Research, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Department of Infectious Diseases and The National Centre for Infections in Cancer, Parkville, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases, Vanderbilt University Medical Centre, Nashville, Tennessee-
dc.identifier.doi10.1001/jamainternmed.2020.0403-
dc.identifier.orcid0000-0002-5111-6367-
dc.identifier.pubmedid32176248-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.